Corcept Therap Drug Patent Portfolio

Corcept Therap owns 1 orange book drug protected by 17 US patents Given below is the list of Corcept Therap's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10231983 Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients 22 Aug, 2038
Active
US10314850 Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients 22 Aug, 2038
Active
US10780097 Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients 22 Aug, 2038
Active
US10195214 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors 19 Jun, 2037
Active
US10842800 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors 19 Jun, 2037
Active
US11969435 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors 19 Jun, 2037
Active
US10151763 Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome 18 Jan, 2037
Active
US9829495 Method for differentially diagnosing ACTH-dependent Cushing's syndrome 15 Aug, 2036
Active
US10006924 Method for differentially diagnosing ACTH-dependent cushing's syndrome 12 Aug, 2036
Active
US10495650 Method for differentially diagnosing ACTH-dependent Cushing's syndrome 12 Aug, 2036
Active
US10166242 Optimizing mifepristone levels for Cushing's patients 20 Apr, 2036
Active
US10166243 Optimizing mifepristone levels for cushing'S patients 20 Apr, 2036
Active
US10660904 Optimizing mifepristone levels for cushing's patients 20 Apr, 2036
Active
US9943526 Optimizing mifepristone levels for cushing's patients 20 Apr, 2036
Active
US10500216 Optimizing mifepristone absorption 05 Mar, 2033
Active
US10842801 Optimizing mifepristone absorption 15 Nov, 2032
Active
US8921348 Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists 27 Aug, 2028
Active


Given below is the list of recent legal activities going on the following drug patents of Corcept Therap.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 08 May, 2024 US10842800
Payment of Maintenance Fee, 4th Yr, Small Entity 08 May, 2024 US10842801
Payment of Maintenance Fee, 4th Yr, Small Entity 06 Mar, 2024 US10780097
Payment of Maintenance Fee, 4th Yr, Small Entity 08 Nov, 2023 US10660904
Payment of Maintenance Fee, 4th Yr, Small Entity 24 May, 2023 US10500216
Payment of Maintenance Fee, 4th Yr, Small Entity 17 May, 2023 US10495650
Payment of Maintenance Fee, 4th Yr, Small Entity 23 Nov, 2022 US10314850
Payment of Maintenance Fee, 4th Yr, Small Entity 07 Sep, 2022 US10231983
Review Certificate Mailed 03 Aug, 2022 US10195214
AIA Appeal returned from Federal Circuit 25 Jul, 2022 US10195214
Review Certificate 25 Jul, 2022 US10195214
Payment of Maintenance Fee, 4th Yr, Small Entity 20 Jul, 2022 US10195214
Payment of Maintenance Fee, 4th Yr, Small Entity 15 Jun, 2022 US10166242
Payment of Maintenance Fee, 4th Yr, Small Entity 15 Jun, 2022 US10166243
Payment of Maintenance Fee, 4th Yr, Small Entity 25 May, 2022 US10151763


Corcept Therap's Drug Patent Litigations

Corcept Therap's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 02, 2018, against patent number US8921348. The petitioner Neptune Generics LLC, challenged the validity of this patent, with Corcept Therapeutics Inc. as the respondent. Click below to track the latest information on how companies are challenging Corcept Therap's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10195214 May, 2019 FWD Entered
(18 Nov, 2020)
Corcept Therapeutics, Inc. Teva Pharmaceuticals USA, Inc.
US8921348 August, 2018 FWD Entered
(10 Feb, 2020)
Corcept Therapeutics Inc. Neptune Generics LLC


Corcept Therap's Family Patents

Corcept Therap drugs have patent protection in a total of 12 countries. It has a significant patent presence in the US with 59.4% of its patents being US patents. Click below to unlock the full patent family tree.

Family Patents



Corcept Therap Drug List

Given below is the complete list of Corcept Therap's drugs and the patents protecting them.


1. Korlym

Korlym is protected by 17 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10231983 Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients 22 Aug, 2038
(13 years from now)
Active
US10314850 Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients 22 Aug, 2038
(13 years from now)
Active
US10780097 Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients 22 Aug, 2038
(13 years from now)
Active
US10195214 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors 19 Jun, 2037
(12 years from now)
Active
US10842800 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors 19 Jun, 2037
(12 years from now)
Active
US11969435 Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors 19 Jun, 2037
(12 years from now)
Active
US10151763 Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome 18 Jan, 2037
(12 years from now)
Active
US9829495 Method for differentially diagnosing ACTH-dependent Cushing's syndrome 15 Aug, 2036
(11 years from now)
Active
US10006924 Method for differentially diagnosing ACTH-dependent cushing's syndrome 12 Aug, 2036
(11 years from now)
Active
US10495650 Method for differentially diagnosing ACTH-dependent Cushing's syndrome 12 Aug, 2036
(11 years from now)
Active
US10166242 Optimizing mifepristone levels for Cushing's patients 20 Apr, 2036
(11 years from now)
Active
US10166243 Optimizing mifepristone levels for cushing'S patients 20 Apr, 2036
(11 years from now)
Active
US10660904 Optimizing mifepristone levels for cushing's patients 20 Apr, 2036
(11 years from now)
Active
US9943526 Optimizing mifepristone levels for cushing's patients 20 Apr, 2036
(11 years from now)
Active
US10500216 Optimizing mifepristone absorption 05 Mar, 2033
(8 years from now)
Active
US10842801 Optimizing mifepristone absorption 15 Nov, 2032
(8 years from now)
Active
US8921348 Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists 27 Aug, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Korlym's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List